Please login to the form below

Not currently logged in
Email:
Password:

Portola

This page shows the latest Portola news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

Latest news

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Bad news for Portola as CHMP considers Factor Xa drugs. The committee are ‘unlikely’to adopt a positive opinion for betrixaban. ... Portola Pharmaceuticals’efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in

  • Portola rejection hands advantage to Boehringer's Pradaxa Portola rejection hands advantage to Boehringer's Pradaxa

    Portola rejection hands advantage to Boehringer's Pradaxa. FDA’ s ruling on reversal agent for NOACs unexpected. ... The agency said that it also needs more time to complete its review of certain clinical amendments to Portola's post-marketing

  • Boehringer’s Praxbind granted accelerated approved by FDA Boehringer’s Praxbind granted accelerated approved by FDA

    However, competition is also coming from rivals such as Portola Pharmaceuticals, which is currently undertaking phase III trials of andexanet alfa, which has shown to reverse the effect of other

  • Novel anticoagulant antidotes prove their worth Novel anticoagulant antidotes prove their worth

    Novel anticoagulant antidotes prove their worth. Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials. ... Portola is collaborating with the companies developing all three of the Factor Xa inhibitors, while Daiichi

  • Boehringer steals lead among NOACs with Pradaxa antidote Boehringer steals lead among NOACs with Pradaxa antidote

    Antidotes are also being developed for Pradaxa's rivals, with Portola Pharmaceuticals currently conducting phase III trials of andexanet alfa, which has been shown to reverse the effects of Eliquis, Xarelto ... Portola has collaborations in place with

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence, collaboration. 237.5. Portola Pharmaceuticals/ HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Portola is also developing PRT 064445, which is an

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    He joins the Palma-headquartered company from Portola Pharmaceuticals, where he served as a senior vice president and head of clinical development. ... Prior to his time at Portola, Dr Gold was head of clinical development at Reata Pharmaceuticals and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics